Even mild hemolysis in paroxysmal nocturnal hemoglobinuria could severely compromise the quality of life due to long-term sustained intolerant fatigue

This publication has 13 references indexed in Scilit:

• Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry
  Annals of Hematology, 2020
• Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)—a report on phase III
  Annals of Hematology, 2019
• Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study
  Blood, 2019
• Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan
  International Journal of Hematology, 2018
• Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status
  Blood Cells, Molecules, and Diseases, 2017
• Paroxysmal nocturnal haemoglobinuria: to prednisone or not to prednisone? – a case report of a patient previously treated with steroids for 15 yrs and significant response on eculizumab
  European Journal of Haematology, 2015
• Paroxysmal nocturnal hemoglobinuria
  Blood, 2014
• Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
  Blood, 2008
• Quality of life research within the EORTC—the EORTC QLQ-C30
  European Journal of Cancer, 2002
• Fatigue in cancer patients compared with fatigue in the general United States population
  Cancer, 2002